Sarepta Therapeutics (SRPT) Tops Q3 EPS by 7c; Raises FY Revenue outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Sarepta Therapeutics (SRPT) PT Raised to $60 at Piper Jaffray
October 26, 2017 4:36 AM EDTPiper Jaffray raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $60.00 (from $55.00) while maintaining a Overweight rating.
Analyst Ed Tenthoff likes the third consecutive beat by Exondys51 on sales and raises his expectations for future sales which drives his PT higher.
... More